Resveratrol acts as a topoisomerase II poison in human glioma cells

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages

  Leone, Stefano ^a   Basso, Emiliano ^a   Polticelli, Fabio ^a,b   Cozzi, Renata ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b INFN SEZIONE DI ROMA   (Italy)

Author keywords

DNA damage signalling; DNA TOPO cleavable complex; docking simulation; micronuclei

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CELL DNA; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HISTONE H2AX; RESVERATROL; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG PROTEIN BINDING; DRUG TARGETING; GLIOMA CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; MICRONUCLEUS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GLIOMA; HISTONES; HUMANS; MODELS, MOLECULAR; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; STILBENES; TOPOISOMERASE II INHIBITORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84861572311     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27358     Document Type: Article

References (36)

1. Gatz SA, Wiesmuller L,. Take a break - resveratrol in action on DNA. Carcinogenesis 2008; 29: 321-32.
2. Kraft TE, Parisotto D, Schempp C, Efferth T,. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 2009; 49: 782-99.
3. Zheng LF, Wei QY, Cai YJ, Fang JG, Zhou B, Yang L, Liu ZL,. DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu (II) ions: mechanism and structure-activity relationship. Free Radic Biol Med 2006; 41: 1807-16.
4. Snyder RD, Gillies PJ,. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ Mol Mutagen 2002; 40: 266-76.
5. Bandele OJ, Osheroff N,. Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 2007; 46: 6097-108.
6. Nitiss JL,. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9: 327-37.
7. Heck MM, Earnshaw WC,. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986; 103: 2569-81.
8. Hsiang YH, Wu HY, Liu LF,. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48: 3230-5.
9. Larsen AK, Escargueil AE, Skladanowski A,. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99: 167-81.
10. Felix CA,. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001; 36: 525-35.
11. Leone S, Cornetta T, Basso E, Cozzi R,. Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction. Cancer Lett 2010; 295: 167-72.
12. Yamada M, Hayashi K, Hayashi H, Tsuji R, Kakumoto K, Ikeda S, Hoshino T, Tsutsui K, Ito T, Iinuma M, Nozaki H,. Nepalensinols D-G, new resveratrol oligomers from Kobresia nepalensis (Cyperaceae) as potent inhibitors of DNA topoisomerase II. Chem Pharm Bull 2006; 54: 354-8.
13. Bandele OJ, Osheroff N,. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. Biochemistry 2008; 47: 11900-8.
14. Dong KC, Berger JM,. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 2007; 450: 1201-5.
15. Schneidman-Duhovny D, Inbar Y, Polak V, Shatsky M, Halperin I, Benyamini H, Barzilai A, Dror O, Haspel N, Nussinov R, Wolfson HJ,. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 2003; 52: 107-12.
16. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT,. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995; 55: 2097-103.
17. Fenech M,. The in vitro micronucleus technique. Mutat Res 2000; 455: 81-95.
18. Leone S, Fiore M, Lauro MG, Pino S, Cornetta T, Cozzi R,. Resveratrol and X rays affect gap junction intercellular communications in human glioblastoma cells. Mol Carcinog 2008; 47: 587-98.
19. Subramanian D, Furbee CS, Muller MT,. ICE bioassay. Isolating in vivo complexes of enzyme to DNA. Methods Mol Biol 2001; 95: 137-47.
20. Henwood JM, Brogden RN,. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39: 438-90.
21. Michel B, Ehrlich SD, Uzest M,. DNA double-strand breaks caused by replication arrest. EMBO J 1997; 16: 430-8.
22. Fenech M, Kirsch-Volders M, Natarajan AT, Surralles J, Crott JW, Parry J, Norppa H, Eastmond DA, Tucker JD, Thomas P,. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 2011; 26: 125-32.
23. Bryce SM, Bemis JC, Avlasevich SL, Dertinger SD,. In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutat Res 2007; 630: 78-91.
24. Gagliano N, Aldini G, Colombo G, Rossi R, Colombo R, Gioia M, Milzani A, Dalle-Donne I,. The potential of resveratrol against human gliomas. Anticancer Drugs 2010; 21: 140-50.
25. Heiss EH, Schilder YD, Dirsch VM,. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 2007; 282: 26759-66.
26. Azmi AS, Bhat SH, Hanif S, Hadi SM,. Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. FEBS Lett 2006; 580: 533-8.
27. Cao G, Sofic E, Prior RL,. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 1997; 22: 749-60.
28. Sánchez Y, Calle C, de Blas E, Aller P,. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. Chem Biol Interact 2009; 182: 37-44.
29. Corbett AH, Osheroff N,. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993; 6: 585-97.
30. McClendon AK, Osheroff N,. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 2007; 623: 83-97.
31. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R,. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 2005; 26: 1978-87.
32. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z,. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 2007; 6: 371-6.
33. Park I, Avraham HK,. Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. Exp Cell Res 2006; 312: 1996-2008.
34. Kumagai A, Dunphy WG,. How cells activate ATR. Cell Cycle 2006; 5: 1265-8.
35. Kumagai A, Lee J, Yoo HY, Dunphy WG,. TopBP1 activates the ATR-ATRIP complex. Cell 2006; 124: 943-55.
36. Bakkenist CJ, Kastan MB,. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.